Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats.
DiMartino
M
M
SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.
Wolff
C
C
Patil
A
A
Nambi
P
P
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000473:pathology* / Q000517:prevention & control*; D001381:Azepines / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000187:drug effects / Q000502:physiology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D001381:Azepines; D004791:Enzyme Inhibitors; D011758:Pyrroles; C097660:debromohymenialdisine; C097659:aldisine; D011493:Protein Kinase C; D007213:Indomethacin; D008727:Methotrexate